OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus
Srita Chakka, Rebecca L. Krain, Sarah Ahmed, et al.
Journal of the American Academy of Dermatology (2020) Vol. 84, Iss. 6, pp. 1562-1567
Open Access | Times Cited: 23
Srita Chakka, Rebecca L. Krain, Sarah Ahmed, et al.
Journal of the American Academy of Dermatology (2020) Vol. 84, Iss. 6, pp. 1562-1567
Open Access | Times Cited: 23
Showing 23 citing articles:
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus
Richard Furie, Ronald van Vollenhoven, Kenneth Kalunian, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 10, pp. 894-904
Open Access | Times Cited: 77
Richard Furie, Ronald van Vollenhoven, Kenneth Kalunian, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 10, pp. 894-904
Open Access | Times Cited: 77
An update on clinical trials for cutaneous lupus erythematosus
Lillian Xie, Laís Lopes Almeida Gomes, Caroline J. Stone, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 7, pp. 885-894
Open Access | Times Cited: 8
Lillian Xie, Laís Lopes Almeida Gomes, Caroline J. Stone, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 7, pp. 885-894
Open Access | Times Cited: 8
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
Victoria P. Werth, Roy Fleischmann, Michael Robern, et al.
Lara D. Veeken (2021) Vol. 61, Iss. 6, pp. 2413-2423
Open Access | Times Cited: 46
Victoria P. Werth, Roy Fleischmann, Michael Robern, et al.
Lara D. Veeken (2021) Vol. 61, Iss. 6, pp. 2413-2423
Open Access | Times Cited: 46
Clinical trial outcomes for SLE: what we have and what we need
Laurent Arnaud, Ioannis Parodis, H. Devilliers, et al.
Lupus Science & Medicine (2024) Vol. 11, Iss. 1, pp. e001114-e001114
Open Access | Times Cited: 5
Laurent Arnaud, Ioannis Parodis, H. Devilliers, et al.
Lupus Science & Medicine (2024) Vol. 11, Iss. 1, pp. e001114-e001114
Open Access | Times Cited: 5
The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review
Srita Chakka, Rebecca L. Krain, Josef Symon S. Concha, et al.
Annals of Translational Medicine (2021) Vol. 9, Iss. 5, pp. 431-431
Open Access | Times Cited: 28
Srita Chakka, Rebecca L. Krain, Josef Symon S. Concha, et al.
Annals of Translational Medicine (2021) Vol. 9, Iss. 5, pp. 431-431
Open Access | Times Cited: 28
Comparative responsiveness of cutaneous lupus erythematosus patients to methotrexate and mycophenolate mofetil: A cohort study
Emily Keyes, A. Jobanputra, Rui Feng, et al.
Journal of the American Academy of Dermatology (2021) Vol. 87, Iss. 2, pp. 447-448
Open Access | Times Cited: 17
Emily Keyes, A. Jobanputra, Rui Feng, et al.
Journal of the American Academy of Dermatology (2021) Vol. 87, Iss. 2, pp. 447-448
Open Access | Times Cited: 17
Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus
Sung Kyung Cho, Thomas Vazquez, Victoria P. Werth
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 5, pp. 345-353
Closed Access | Times Cited: 6
Sung Kyung Cho, Thomas Vazquez, Victoria P. Werth
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 5, pp. 345-353
Closed Access | Times Cited: 6
Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need
Lisa N. Guo, Lourdes M. Pérez-Chada, Robert Borucki, et al.
Lupus Science & Medicine (2021) Vol. 8, Iss. 1, pp. e000529-e000529
Open Access | Times Cited: 14
Lisa N. Guo, Lourdes M. Pérez-Chada, Robert Borucki, et al.
Lupus Science & Medicine (2021) Vol. 8, Iss. 1, pp. e000529-e000529
Open Access | Times Cited: 14
Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials
Darosa Lim, Julianne Kleitsch, Victoria P. Werth
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 4, pp. 257-273
Closed Access | Times Cited: 5
Darosa Lim, Julianne Kleitsch, Victoria P. Werth
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 4, pp. 257-273
Closed Access | Times Cited: 5
Expert consensus achieved on a working core outcome set for cutaneous lupus erythematosus research in survey following the 5th International Conference on Cutaneous Lupus Erythematosus (ICCLE)
Arianna Zhang, Lourdes M. Pérez-Chada, Victoria P. Werth, et al.
Lupus Science & Medicine (2024) Vol. 11, Iss. 1, pp. e001165-e001165
Open Access | Times Cited: 1
Arianna Zhang, Lourdes M. Pérez-Chada, Victoria P. Werth, et al.
Lupus Science & Medicine (2024) Vol. 11, Iss. 1, pp. e001165-e001165
Open Access | Times Cited: 1
Management of cutaneous lupus erythematosus
Benjamin F. Chong, Victoria P. Werth
Elsevier eBooks (2024), pp. 802-809
Closed Access | Times Cited: 1
Benjamin F. Chong, Victoria P. Werth
Elsevier eBooks (2024), pp. 802-809
Closed Access | Times Cited: 1
Anifrolumab for systemic lupus erythematosus with multi-refractory skin disease: A case series of 18 patients
Sofia Flouda, Evgenia Emmanouilidou, Αναστάσιος Καραμανάκος, et al.
Lupus (2024) Vol. 33, Iss. 11, pp. 1248-1253
Closed Access | Times Cited: 1
Sofia Flouda, Evgenia Emmanouilidou, Αναστάσιος Καραμανάκος, et al.
Lupus (2024) Vol. 33, Iss. 11, pp. 1248-1253
Closed Access | Times Cited: 1
The Meaning and Reliability of Minimal Important Differences (MIDs) for Clinician-Reported Outcome Measures (ClinROMs) in Dermatology—A Scoping Review
Reinhart Speeckaert, Arno Belpaire, Sandrine Herbelet, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 7, pp. 1167-1167
Open Access | Times Cited: 5
Reinhart Speeckaert, Arno Belpaire, Sandrine Herbelet, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 7, pp. 1167-1167
Open Access | Times Cited: 5
Change in disease activity needed for meaningful change in cutaneous lupus by patient characteristic: A retrospective analysis of a longitudinal database
Julianne Kleitsch, Rachita Pandya, Srita Chakka, et al.
Journal of the American Academy of Dermatology (2023) Vol. 90, Iss. 2, pp. 406-408
Closed Access | Times Cited: 2
Julianne Kleitsch, Rachita Pandya, Srita Chakka, et al.
Journal of the American Academy of Dermatology (2023) Vol. 90, Iss. 2, pp. 406-408
Closed Access | Times Cited: 2
Measurement of specific organ domains in lupus randomized controlled trials: a scoping review
Kathryn Connelly, Jeevan Vettivel, Vera Golder, et al.
Lara D. Veeken (2021) Vol. 61, Iss. 4, pp. 1341-1353
Closed Access | Times Cited: 5
Kathryn Connelly, Jeevan Vettivel, Vera Golder, et al.
Lara D. Veeken (2021) Vol. 61, Iss. 4, pp. 1341-1353
Closed Access | Times Cited: 5
Cutaneous Lupus Erythematosus and Dermatomyositis: Utilizing Assessment Tools for Treatment Efficacy
Benjamin F. Chong, Victoria P. Werth
Journal of Investigative Dermatology (2021) Vol. 142, Iss. 3, pp. 936-943
Open Access | Times Cited: 5
Benjamin F. Chong, Victoria P. Werth
Journal of Investigative Dermatology (2021) Vol. 142, Iss. 3, pp. 936-943
Open Access | Times Cited: 5
Challenging the Tools Used to Measure Cutaneous Lupus Severity in Patients of All Skin Types
Amy McMichael, Cheri Frey
JAMA Dermatology (2024)
Closed Access
Amy McMichael, Cheri Frey
JAMA Dermatology (2024)
Closed Access
Cutaneous Lupus Erythematosus: Expanding Clinical Trial Eligibility Criteria Based on Quality of Life Data
D Faden, Lillian Xie, Caroline J. Stone, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 6, pp. 1203-1205
Closed Access
D Faden, Lillian Xie, Caroline J. Stone, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 6, pp. 1203-1205
Closed Access
Severity Scores for Cutaneous Lupus Erythematosus
Tyler B Cepica, Radhika Gupta, Victoria P. Werth, et al.
Journal of Investigative Dermatology (2024)
Closed Access
Tyler B Cepica, Radhika Gupta, Victoria P. Werth, et al.
Journal of Investigative Dermatology (2024)
Closed Access
The Psychosocial Impact of Immune-Mediated Skin Diseases
Jonathan D. Greenzaid, Nicholas R. Kiritsis, Brittany Chandani, et al.
Integrated science (2024), pp. 601-628
Closed Access
Jonathan D. Greenzaid, Nicholas R. Kiritsis, Brittany Chandani, et al.
Integrated science (2024), pp. 601-628
Closed Access
Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspective
Joy Buie, Lauren Bloch, Eric F. Morand, et al.
Lupus Science & Medicine (2023) Vol. 10, Iss. 1, pp. e000901-e000901
Open Access | Times Cited: 1
Joy Buie, Lauren Bloch, Eric F. Morand, et al.
Lupus Science & Medicine (2023) Vol. 10, Iss. 1, pp. e000901-e000901
Open Access | Times Cited: 1
Preliminary definition of flare in cutaneous lupus erythematosus using the Cutaneous Lupus Erythematosus Disease Area and Severity Index
Emily Keyes, Robert Borucki, Rui Feng, et al.
Journal of the American Academy of Dermatology (2021) Vol. 87, Iss. 2, pp. 418-419
Open Access | Times Cited: 3
Emily Keyes, Robert Borucki, Rui Feng, et al.
Journal of the American Academy of Dermatology (2021) Vol. 87, Iss. 2, pp. 418-419
Open Access | Times Cited: 3
Filgotinib in cutaneous lupus: is a negative positive?
Kathryn Connelly, Eric F. Morand
Lara D. Veeken (2021) Vol. 61, Iss. 6, pp. 2213-2214
Open Access
Kathryn Connelly, Eric F. Morand
Lara D. Veeken (2021) Vol. 61, Iss. 6, pp. 2213-2214
Open Access
